These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9408857)

  • 1. Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.
    Cosson VF; Fuseau E; Efthymiopoulos C; Bye A
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):149-67. PubMed ID: 9408857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
    Cosson VF; Fuseau E
    J Pharmacokinet Biopharm; 1999 Apr; 27(2):149-71. PubMed ID: 10567953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interspecies scaling and comparisons in drug development and toxicokinetics.
    Ings RM
    Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling.
    Sanwald-Ducray P; Dow J
    Xenobiotica; 1997 Feb; 27(2):189-201. PubMed ID: 9058532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interspecies allometric scaling in pharmacokinetics of drugs].
    Sylvia M
    Acta Pharm Hung; 1998 Nov; 68(6):350-4. PubMed ID: 9987199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
    Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M
    Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical toxicological evaluation of sumatriptan.
    Owen K; Hartley K; Tucker ML; Parkinson MM; Tweats DJ; Jackson MR
    Hum Exp Toxicol; 1995 Dec; 14(12):959-73. PubMed ID: 8962747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of intranasal sumatriptan.
    Fuseau E; Petricoul O; Moore KH; Barrow A; Ibbotson T
    Clin Pharmacokinet; 2002; 41(11):801-11. PubMed ID: 12190330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of sumatriptan in laboratory animals and humans.
    Dixon CM; Saynor DA; Andrew PD; Oxford J; Bradbury A; Tarbit MH
    Drug Metab Dispos; 1993; 21(5):761-9. PubMed ID: 7902233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sumatriptan (Imitrex) transport by the human placenta.
    Schenker S; Yang Y; Perez A; Henderson GI; Lee MP
    Proc Soc Exp Biol Med; 1995 Dec; 210(3):213-20. PubMed ID: 8539258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of NS-49, a phenethylamine class alpha(1A)-adrenoceptor agonist, at therapeutic doses in several animal species and interspecies scaling of its pharmacokinetic parameters.
    Mukai H; Watanabe S; Tsuchida K; Morino A
    Int J Pharm; 1999 Sep; 186(2):215-22. PubMed ID: 10486440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog.
    Barrow A; Dixon CM; Saynor DA; Perren MJ; Stowe R; Smith I
    Biopharm Drug Dispos; 1997 Jul; 18(5):443-58. PubMed ID: 9210982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase.
    Kamel A; Colizza K; Gunduz M; Harriman S; Obach RS
    Xenobiotica; 2012 Apr; 42(4):355-62. PubMed ID: 22106962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
    Hurwitz SJ; Otto MJ; Schinazi RF
    Antivir Chem Chemother; 2005; 16(2):117-27. PubMed ID: 15889534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
    Kim SH; Kim WB; Lee MG
    Biopharm Drug Dispos; 1998 May; 19(4):231-5. PubMed ID: 9604122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic parameters for interspecies scaling using allometric techniques.
    Hayton WL
    Health Phys; 1989; 57 Suppl 1():159-64. PubMed ID: 2606679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation.
    Fox AW
    Headache; 2004 Feb; 44(2):142-7. PubMed ID: 14756852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.